Mir O - Search Results

1

Pharmacokinetic interaction involving fenofibrate and everolimus.

Mir O, Poinsignon V, Arnedos M, Delaloge S, Paci A. Mir O, et al. Ann Oncol. 2015 Jan;26(1):248-249. doi: 10.1093/annonc/mdu492. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361989 Free article. No abstract available.

2

Emerging therapeutic options for breast cancer chemotherapy during pregnancy.

Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, Goldwasser F. Mir O, et al. Ann Oncol. 2008 Apr;19(4):607-13. doi: 10.1093/annonc/mdm460. Epub 2007 Oct 5. Ann Oncol. 2008. PMID: 17921242 Free article. Review.

3

Taxanes for breast cancer during pregnancy: a systematic review.

Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, Rouzier R. Mir O, et al. Ann Oncol. 2010 Feb;21(2):425-426. doi: 10.1093/annonc/mdp517. Epub 2009 Nov 3. Ann Oncol. 2010. PMID: 19887464 Free article. Review. No abstract available.

4

Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting.

Rouzier R, Werkoff G, Uzan C, Mir O, Gligorov J, Selleret L, Goffinet F, Goldwasser F, Treluyer JM, Uzan S, Delaloge S. Rouzier R, et al. Among authors: mir o. Ann Oncol. 2011 Jul;22(7):1582-1587. doi: 10.1093/annonc/mdq642. Epub 2011 Jan 17. Ann Oncol. 2011. PMID: 21242588 Free article.

5

Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications.

Mir O, Coriat R, Boudou-Rouquette P, Durand JP, Goldwasser F. Mir O, et al. Ann Oncol. 2012 Jan;23(1):280-281. doi: 10.1093/annonc/mdr525. Epub 2011 Nov 4. Ann Oncol. 2012. PMID: 22056851 Free article. No abstract available.

6

Objective response to sorafenib in advanced clear-cell sarcoma.

Mir O, Boudou-Rouquette P, Larousserie F, Babinet A, Dumaine V, Anract P, Goldwasser F. Mir O, et al. Ann Oncol. 2012 Mar;23(3):807-809. doi: 10.1093/annonc/mds005. Epub 2012 Jan 24. Ann Oncol. 2012. PMID: 22274882 Free article. No abstract available.

7

Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.

Berveiller P, Selleret L, Mir O. Berveiller P, et al. Among authors: mir o. Ann Oncol. 2014 Oct;25(10):1869-1870. doi: 10.1093/annonc/mdu376. Epub 2014 Aug 14. Ann Oncol. 2014. PMID: 25125694 Free article. No abstract available.

8

Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.

Jovelet C, Seck A, Mir O, Simasotchi C, Broutin S, Goffinet F, Bidart JM, Paci A, Gil S. Jovelet C, et al. Among authors: mir o. Ann Oncol. 2015 Jul;26(7):1500-4. doi: 10.1093/annonc/mdv172. Epub 2015 Apr 7. Ann Oncol. 2015. PMID: 25851627 Free article.

9

Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?

Mir O, Dumont S, Armand JP. Mir O, et al. Ann Oncol. 2015 Jul;26(7):1277-8. doi: 10.1093/annonc/mdv246. Epub 2015 Jun 15. Ann Oncol. 2015. PMID: 26078469 Free article. No abstract available.

10

Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.

Voican CS, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, Chaussade S, Pol S, Coriat R. Voican CS, et al. Among authors: mir o. Ann Oncol. 2016 Dec;27(12):2172-2184. doi: 10.1093/annonc/mdw414. Epub 2016 Nov 1. Ann Oncol. 2016. PMID: 27803003 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

342 results

Search Page

Filters